The antibiotics market would grow at a CAGR of 8.9% over the predicted time frame. The market is expected to increase in value from US$ 43.26 Bn in 2022 to US$ 59.21 Bn in 2030.
The on antibiotics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/1972
Report Scope of the Antibiotics Market
| Report Coverage | Details |
| Market Size in 2022 | USD 43.236 Billion |
| Market Size by 2030 | USD 59.21 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.9% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel, Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Antibiotics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Antibiotics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Antibiotics market are included as given below:
Antibiotics Market Key Players
- Abbott Laboratories (US)
- Pfizer Inc. (US)
- Johnson & Johnson Services
- GlaxoSmithKline PLC (UK)
- Sanofi (France)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Astellas Pharma Inc. (Japan)
Market Segments
By Drug Class
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolide
- Carbapenem
- Aminoglycoside
- Sulfonamide
- 7-ACA
- Others
By Application
- Skin infections
- Urinary tract infection
- Ear infection
- Septicemia
- Respiratory infections
- Gastrointestinal infections
By Action Mechanism
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors
- Mycolic Acid Inhibitors
- Others
By Drug Origin
- Natural
- Synthetic
By Spectrum Of Activity
- Broad-spectrum Antibiotic
- Narrow-spectrum Antibiotic
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Retail pharmacies
- Online pharmacies
- Hospitals
- Clinics
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global antibiotics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the antibiotics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Antibiotics Market, By Drug Class
7.1. Antibiotics Market, by Drug Class, 2022-2030
7.1.1. Cephalosporin
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Penicillin
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Fluoroquinolone
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Macrolide
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Carbapenem
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Aminoglycoside
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Sulfonamide
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. 7-ACA
7.1.8.1. Market Revenue and Forecast (2017-2030)
7.1.9. 7-Others
7.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Antibiotics Market, By Application
8.1. Antibiotics Market, by Application, 2022-2030
8.1.1. Skin infections
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Urinary tract infection
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Ear infection
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Septicemia
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Respiratory infections
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Gastrointestinal infections
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Antibiotics Market, By Action Mechanism
9.1. Antibiotics Market, by Action Mechanism, 2022-2030
9.1.1. Cell Wall Synthesis Inhibitors
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Protein Synthesis Inhibitors
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. DNA Synthesis Inhibitors
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. RNA Synthesis Inhibitors
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Antibiotics Market, By Drug Origin
10.1. Antibiotics Market, by Drug Origin, 2022-2030
10.1.1. Natural
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Synthetic
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Antibiotics Market, By Spectrum Of Activity
11.1. Antibiotics Market, by Spectrum Of Activity, 2022-2030
11.1.1. Broad-spectrum Antibiotic
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Narrow-spectrum Antibiotic
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Antibiotics Market, By Route of Administration
12.1. Antibiotics Market, by Route of Administration, 2022-2030
12.1.1. Oral
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Parenteral
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Antibiotics Market, By Distribution Channel
13.1. Antibiotics Market, by Distribution Channel, 2022-2030
13.1.1. Retail pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Online pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Hospitals
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Clinics
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Antibiotics Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.1.2. Market Revenue and Forecast, by Application (2017-2030)
14.1.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.1.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.1.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Application (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.2.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.2.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Application (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.3.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.3.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Application (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.4.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.4.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Application (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.5.2. Market Revenue and Forecast, by Application (2017-2030)
14.5.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.5.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.5.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Application (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Application (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Action Mechanism (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Drug Origin (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Spectrum Of Activity (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)
Chapter 15. Company Profiles
15.1. Abbott Laboratories (US)
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Pfizer Inc. (US)
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Johnson & Johnson Services
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. GlaxoSmithKline PLC (UK)
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Sanofi (France)
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Bristol-Myers Squibb Company (US)
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Eli Lilly and Company (US)
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Novartis AG (Switzerland)
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Bayer AG (Germany)
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Astellas Pharma Inc. (Japan)
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments